Inflammatory Bowel Disease in Pregnancy

  • Sunanda KaneEmail author


While the incidence of ulcerative colitis has remained stable, the incidence of Crohn disease [CD] has increased over the past few decades. It is not clear whether this is due to improved diagnostic techniques, an increase in smoking habits by young female patients [patients with CD tend to be smokers compared to people without CD], environmental or genetic influences, or other factors not yet identified. However, the consequence of this trend is a growing population of patients in their formative and childbearing years.


Crohn disease Ulcerative colitis Pediatric Pregnancy Teratogenicity 


  1. 1.
    Peyrin-Biroulet L, Loftus Jr EV, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn disease in population-based cohorts. Inflamm Bowel Dis. 2011;17(1):471–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB. Cigarette smoking in Crohn disease. Am J Gastroenterol. 1989;84:31–3.PubMedGoogle Scholar
  3. 3.
    Suris JC, Resnick MD, Cassuto N, Blum RW. Sexual behavior of adolescents with chronic disease and disability. J Adolesc Health. 1996;19(2):124–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Newacheck P, Halfon N. Prevalence and impact of disabling chronic conditions in childhood. Am J Public Health. 1998;88:610–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Gittes EB, Strickland JL. Contraceptive choices for chronically Ill adolescents. Adolesc Med. 2005;16:635–44.CrossRefGoogle Scholar
  6. 6.
    Gawron LM, Gawron AJ, Kasper A, Hammond C, Keefer L. Contraceptive method selection by women with inflammatory bowel diseases: a cross-sectional study. Contraception. 2014;89:419–25.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Wakeman J. Exacerbation of Crohn disease after insertion of a levonorgestrel intrauterine system: a case report. J Fam Plann Reprod Health Care. 2003;29(3):154.PubMedCrossRefGoogle Scholar
  8. 8.
    Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn disease. The Canadian Mesalamine for Remission of Crohn Disease Study Group. Gastroenterol. 1998;114(6):1143–50.CrossRefGoogle Scholar
  9. 9.
    Cornish JA, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394–400.PubMedCrossRefGoogle Scholar
  10. 10.
    Cottone M, Camma C, Orlando A, et al. Oral contraceptive and recurrence in Crohn disease. Gastroenterol. 1999;116:A693.CrossRefGoogle Scholar
  11. 11.
    Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM. Contraceptive use among women with inflammatory bowel disease: a systematic review. Contraception. 2010;82:72–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Gawron LM, Goldberger A, Gawron AJ, Hammond C, Keefer L. The impact of hormonal contraception on disease-related cyclical symptoms in women with inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1729–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Coley RL, Chase-Lansdale PL. Adolescent pregnancy and parenthood: recent evidence and future direction. Am Psychol. 1998;53:152–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn disease: a case control study by European collaborative group. Gut. 1986;27:821–5.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Tiverneir N, Fumery M, Peyri-Biroulet L, Coumbel JF, Gower-Russen C. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Thera. 2013;38:847–53.CrossRefGoogle Scholar
  16. 16.
    Ban L, Tata LJ, Humes DJ, Fiaschi L, Card T. Decreased fertility rates in 639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther. 2015;42(7):855–66.PubMedCrossRefGoogle Scholar
  17. 17.
    Oza SS, Pabby V, Dodge LE, et al. In vitro fertilization in women with inflammatory bowel disease is as successful as in women from the general infertility population. Clin Gastroenterol Hepatol. 2015;13:1641–6.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut. 1981;22:452–5.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Burnell D, Mayberry J, Calcraft BJ, Morris JS, Rhodes J. Male fertility in Crohn disease. Postgrad Med J. 1986;62:269–72.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Dejaco C, Mittemaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterol. 2001;121:1048–53.CrossRefGoogle Scholar
  21. 21.
    Nørgård B, Pedersen L, Jacobsen J, Rasmussen SN, Sørensen HT. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther. 2004;19(6):679–85.PubMedCrossRefGoogle Scholar
  22. 22.
    Rajapakse RO, Korelitz BI, Zlatanic J, Baiocco PJ, Gleim GW. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 2000;95(3):684–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Banks B, Korelitz BI, Zetzel L. The course of non-specific ulcerative colitis: a review of twenty years of experience and late results. Gastroenterol. 1957;32:983–1012.Google Scholar
  24. 24.
    Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med. 1986;79:221–5.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980;21:469–74.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Moser MA, Okun NB, Mayes DC, Bailey RJ. Crohn disease, pregnancy, and birth weight. Am J Gastroenterol. 2000;95:1021–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56(6):830–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Porter RJ, Stirrat GM. The effects of inflammatory bowel disease on pregnancy: a case- controlled retrospective analysis. Br J Obstet Gynaecol. 1986;93:1124–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol. 2012;10:1246–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Kane SV, Hanauer SB, Kiesel J, Shih L, Tyan D. HLA disparity determines disease activity through pregnancy in women with IBD. Am J Gastroenterol. 2004;99(8):1523–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Nwokolo C, Tan WC, Andrews HA, Allan RN. Surgical resections in parous patients with distal ileal and colonic Crohn disease. Gut. 1994;35:220–3.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Riis L, Vind I, Politi P, et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101(7):1539–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Shoenut JP, Semelka RC, Silverman R, Yaffe CS, Micflikier AB. MRI in the diagnosis of Crohn disease in two pregnant women. J Clin Gastroenterol. 1993;17:244–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol. 1989;16:347–68.PubMedGoogle Scholar
  36. 36.
    Cappell MS, Colon VJ, Sidhom OA. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci. 1996;41:2353–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Qureshi WA, Rajan E, Adler DG, et al. ASGE guideline: guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc. 2005;61(3):357–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Friedel D, Stavropoulos S, Iqbal S, Cappell MS. Gastrointestinal endoscopy in the pregnant woman. World J Gastrointest Endo. 2014;6:156–67.CrossRefGoogle Scholar
  39. 39.
    Sachar D. Exposure to mesalamine during pregnancy increased preterm deliveries (but not birth defects) and decreased birth weight. Gut. 1998;43:316.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Warrell DW, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet. 1968;1:117–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Coelho J, Beaugerie L, Colombel JF. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60(2):198–203.PubMedCrossRefGoogle Scholar
  42. 42.
    Einarson A, Mastroiacovo P, Arnon J, et al. Prospective, controlled multicenter study of loperamide in pregnancy. Can J Gastroenterol. 2000;14:185–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Bonapace E, Fisher RS. Constipation and diarrhea in pregnancy. Gastroenterol Clin NA. 1998;27:197–211.CrossRefGoogle Scholar
  44. 44.
    Briggs G, Freeman R, Yaffee S. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. New Jersey: Lippincott Williams & Wilkins; 2008.Google Scholar
  45. 45.
    Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003;3:81–92.PubMedGoogle Scholar
  46. 46.
    Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediart Sand. 1987;76:137–42.CrossRefGoogle Scholar
  47. 47.
    Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and female patients with inflammatory bowel disease in Leicestershire. Int J Color Dis. 1997;12:220–4.CrossRefGoogle Scholar
  48. 48.
    Hernandez-Diaz S, Werler MM, Mitchell AA, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–14.PubMedCrossRefGoogle Scholar
  49. 49.
    Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25(2):271–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? [letter] [see comments]. Lancet. 1994;344:620–1.PubMedCrossRefGoogle Scholar
  51. 51.
    Hernández-Díaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect. 2009;117(2):185–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Diav-Citrin O, Shechtman S, Ornoy A, et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology. 2001;63:186–92.PubMedCrossRefGoogle Scholar
  53. 53.
    Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol. 1993;82:348–52.PubMedGoogle Scholar
  54. 54.
    Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol. 1995;28:59–64.PubMedCrossRefGoogle Scholar
  55. 55.
    Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99:656–61.PubMedCrossRefGoogle Scholar
  56. 56.
    Loebstein R, Addis A, HO E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998;42:1336–9.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Beitins IZ, Bayard F, Migeon CJ, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81:936–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Mogadam M, Korelitz BI, Ahmed SW, Dobbins WD, Baiocco PJ. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol. 1981;75:265–9.PubMedGoogle Scholar
  59. 59.
    Armenti V, Ahlswede KM, Ahlswede RA, et al. National transplant pregnancy registry-outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation. 1994;57(4):502–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Ramsey-Goldman RSE. Immunosuppressive drug use during pregnancy. Rheum Clin NA. 1997;23:149–67.CrossRefGoogle Scholar
  61. 61.
    Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115:1100–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731–43.PubMedCrossRefGoogle Scholar
  63. 63.
    Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs. (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol. 2004;18:219–30.PubMedCrossRefGoogle Scholar
  64. 64.
    Francella A, Dyan A, Present DH, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9–17.PubMedCrossRefGoogle Scholar
  65. 65.
    Norgard B, Pedersen L, Sorensen HT, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther. 2003;17:827–34.PubMedCrossRefGoogle Scholar
  66. 66.
    Goldenberg M, Bider D, Oelsner G, et al. Methotrexate therapy of tubal pregnancy. Hum Reprod. 1993;8:660–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Gromnica-Ihle E, Kruger K. Use of methotrexate in young patients with regard to the reproductive system. Clin Exp Rheum. 2010;28:S80–4.Google Scholar
  68. 68.
    Katz JA, Antoni C, Lichenstein GR, et al. Outcome of pregnancy in female patients receiving infliximab for the treatment of Crohn disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–92.PubMedCrossRefGoogle Scholar
  69. 69.
    Kane SV, Acquah LA, Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106(2):214–23.CrossRefGoogle Scholar
  70. 70.
    Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Thera. 2014;40:363–73.CrossRefGoogle Scholar
  71. 71.
    Mahadevan U, Wolf DC, Dubinsky MC, et al. Placental transfer of anti tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–92.PubMedCrossRefGoogle Scholar
  72. 72.
    Pasut G. Pegylation of biological molecules and potential benefits: pharmacologic properties of certolizumab pegol. BioDrugs. 2014;28:S15–30.PubMedCrossRefGoogle Scholar
  73. 73.
    Zelenkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318–21.CrossRefGoogle Scholar
  74. 74.
    Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63.PubMedCrossRefGoogle Scholar
  75. 75.
    Vedolizumab Prescribing Information. 2014 Takeda. Accessed at on Dec 30, 2016.
  76. 76.
    Motta M, Ciardelli L, Marconi M, et al. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J Perinatol. 2007;24(8):441–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Khan HA. Cyclosporin-A augments respiratory burst of whole blood phagocytes in pregnant rats. Immunopharmacol Immunotoxicol. 2007;29(3–4):367–74.PubMedCrossRefGoogle Scholar
  78. 78.
    Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin N Am. 1997;23:149–67.CrossRefGoogle Scholar
  79. 79.
    Bertschinger P, Himmelmann A, Follath F, et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol. 1995;90:330.PubMedGoogle Scholar
  80. 80.
    Kornbluth A, Reddy D. Management and outcome of severe colitis in pregnancy. Am J Gastroenterol. 2002;97:P705.CrossRefGoogle Scholar
  81. 81.
    Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn disease: an open-label trial. Gastroenterol. 1999;117:1271–7.CrossRefGoogle Scholar
  82. 82.
    Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn disease. Gastroenterology. 1999;117:1278–87.PubMedCrossRefGoogle Scholar
  83. 83.
    Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of compicated proximal small bowel and fistulizing Crohn disease. Am J Gastroenterol. 1997;92:876–9.PubMedGoogle Scholar
  84. 84.
    Neurath MF, Wanitschke R, Peters M. Randomized trial of mycophenolate versus azathioprine for treatment of chronic active Crohn disease. Gut. 1999;44:625–8.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in female patients treated systemically with tacrolimus. Transpl Int. 2000;13:S299–300.PubMedCrossRefGoogle Scholar
  86. 86.
    Jacobson L, Clapp DH. Total parenteral nutrition in pregnancy complicated by Crohn disease. JPEN. 1987;11:93–6.CrossRefGoogle Scholar
  87. 87.
    Nugent F, Rajala M, O’Shea RA, et al. Total parenteral nutrition in pregnancy: conception to delivery. JPEN. 1987;11:424–7.CrossRefGoogle Scholar
  88. 88.
    Park YK, Meier ER, Song WO. Characteristics of teenage mothers and predictors of breastfeeding initiation in the Michigan WIC Program in 1995. Women, infants, and children. J Hum Lact. 2003;19:50–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005;100(1):102–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol. 2009;104(10):2517–23.PubMedCrossRefGoogle Scholar
  91. 91.
    Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet. 1993;342:618–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Nelis GF. Diarrhoea due to 5-aminosalicyclic acid in breast milk. Lancet. 1989;1:383.PubMedCrossRefGoogle Scholar
  93. 93.
    Christensen LA. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man. Dan Med Bull. 2000;47(1):20–41.PubMedGoogle Scholar
  94. 94.
    Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28(10):1209–13.PubMedCrossRefGoogle Scholar
  95. 95.
    Nyberg G, Haljamae U, Kjemeller I, et al. Breast-feeding during treatment with cyclosporine. Transplantation. 1998;65:253–5.PubMedCrossRefGoogle Scholar
  96. 96.
    Munoz-Flores-Thiagarajan KD, Easterling T, Bond EF, et al. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol. 2001;97:816–8.PubMedGoogle Scholar
  97. 97.
    Ost L, Wettrell G, Rane A, et al. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–11.PubMedCrossRefGoogle Scholar
  98. 98.
    Kane S. Breastfeeding and IBD: safety and management issues. Inflamm Bowel Dis Monit. 2004;6:50–2.Google Scholar
  99. 99.
    Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn disease before and after delivery. J Clin Gastroenterol. 2009;43(7):613–6.PubMedCrossRefGoogle Scholar
  100. 100.
    Ben Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Gibert WM, Jandial D, Field NT, et al. Birth outcomes in teenage pregnancies. J Matern Fetal Neonatal Med. 2004;16:265–70.CrossRefGoogle Scholar
  102. 102.
    Ilnyckyj A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn disease and pregnancy: role of the mode of delivery. Am J Gastroenterol. 1999;94:3274–8.CrossRefGoogle Scholar
  103. 103.
    Cheng A, Oxford EC, Sauk J, et al. Impact of mode of delivery on outcomes in patients with perianal Crohn disease. Inflamm Bowel Dis. 2014;20:1391–8.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Ananthakrishnan A, Cheng A, Cagan A, et al. Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases. Dig Dis Sci. 2015;60:471–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Levine W, Diamond B. Surgical procedures during pregnancy. Am J Obstet Gynecol. 1961;81:1046–52.PubMedCrossRefGoogle Scholar
  106. 106.
    Kelly M, Hunt TM, Wicks ACB, et al. Fulminant ulcerative colitis and parturition: a need to alter current management? Br J Obstet Gnecol. 1994;101:166–7.CrossRefGoogle Scholar
  107. 107.
    Anderson JB, Turner GM, Williamson RC. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med. 1987;80:492–4.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Hill J, Clark A, Scott NA. Surgical treatment of acute manifestations of Crohn disease during pregnancy. J R Soc Med. 1997;90:64–6.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Metcalf A, Dozois RR, Baert RW, et al. Pregnancy following ileal pouch-anal anastomosis. Dis Colon Rectum. 1985;28:859–61.PubMedCrossRefGoogle Scholar
  110. 110.
    Olsen KOJS, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterol. 2002;122:15–9.CrossRefGoogle Scholar
  111. 111.
    Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575–80.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Pabby V, Oza SS, Dodge LE, et al. In vitro fertilization is successful in women with ulcerative colitis and ileal pouch anal anastomosis. Am J Gastroenterol. 2015;110:792–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Juhasz ES, Fozard B, Dozois RR, Ilstrup DM, Nelson H. Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. Dis Colon Rectum. 1995;38:159–65.PubMedCrossRefGoogle Scholar
  114. 114.
    Baldassano R, Ferry G, Griffiths A. Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology. Hepatol Nutr. 2002;34:245–8.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations